Conclusions : CETP inhibitors are not associated with an increased risk of MACE or all-cause mortality .
There is a trend towards small reductions in nonfatal MI and cardiovascular death , though the clinical importance of such reductions is likely modest
Background : Cholesteryl ester transfer protein ( CETP ) inhibitors increase serum high-density lipoprotein cholesterol ( HDL-c ) concentration ; however , their impact on cardiovascular outcomes is not clear .
This systematic review examines the effect of CETP inhibitors on serum lipid profiles , cardiovascular events , and all-cause mortality .
Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia.
BACKGROUND AND AIMS We aim ed to assess the effects of cholesteryl ester transfer protein inhibitor anacetrapib added to statin ± other lipid-modifying therapies ( LMT ) in Japanese patients with dyslipidemia who were not at their LDL-C goal . METHODS Patients on a stable dose of statin ± other LMT with LDL-C ≥100 mg/dL to < 145 mg/dL , ≥120 mg/dL to < 165 mg/dL , ≥140 mg/dL or ≥160 mg/dL for patients with a history of coronary heart disease ( CHD ) , high- , moderate- and low-risk patients respectively , were r and omized 2:1 , stratified by background therapy , to double-blind anacetrapib 100 mg ( n = 204 ) or placebo ( n = 103 ) for 24 weeks , followed by a 28-week open-label extension phase ( anacetrapib 100 mg ) and a 12-week off-drug safety follow-up phase . The primary endpoint was percent change from baseline in LDL-C ( beta-quantification method ) , as well as the safety profile  of anacetrapib at Week 24 ; HDL-C was a key secondary endpoint . RESULTS Anacetrapib 100 mg further reduced LDL-C ( 38.0 % ) , non-HDL-C ( 35.1 % ) , ApoB ( 28.7 % ) , and Lp(a ) ( 48.3 % ) and increased HDL-C ( 148.9 % ) and ApoAI ( 50.7 % ) versus placebo ( p < 0.001 for all ) . There were no meaningful differences between the groups in the proportion of patients with liver enzymes elevations ( 2.0 % vs. 0 % ) , creatine kinase elevations overall ( 0.5 % vs. 0 % ) or with muscle symptoms ( 0.5 % vs. 0 % ) , blood pressure , electrolytes or adjudicated cardiovascular events ( 0.5 % vs. 0 % ) . In the open-label period , sustained effects on lipid parameters were observed with anacetrapib and the treatment was generally well tolerated . CONCLUSIONS Long-term treatment with anacetrapib 100 mg substantially reduced LDL-C , increased HDL-C and was well tolerated in Japanese patients with dyslipidemia ( Clinical Trials.gov number NCT01760460 )
Conclusions : CETP inhibitors are not associated with an increased risk of MACE or all-cause mortality .
There is a trend towards small reductions in nonfatal MI and cardiovascular death , though the clinical importance of such reductions is likely modest
Background : Cholesteryl ester transfer protein ( CETP ) inhibitors increase serum high-density lipoprotein cholesterol ( HDL-c ) concentration ; however , their impact on cardiovascular outcomes is not clear .
This systematic review examines the effect of CETP inhibitors on serum lipid profiles , cardiovascular events , and all-cause mortality .